Heart Outcomes Prevention Evaluation-3
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Candesartan cilexetil/hydrochlorothiazide (Primary) ; Rosuvastatin (Primary)
- Indications Cardiovascular disorders; Myocardial infarction; Stroke
- Focus Therapeutic Use
- Acronyms HOPE-3
- 08 May 2021 Results (8.7 years of follow-up) published in the European Heart Journal.
- 18 Nov 2019 Results presented at the American Heart Association Scientific Sessions 2019
- 27 Feb 2019 Results (n=2361) published in the Neurology